TH Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.29%

Insider Buying (Last 12 Months): C$91,707.20

Insider Selling (Last 12 Months): C$0.00

Theratechnologies Insider Trading History Chart

Theratechnologies Share Price & Price History

C^$0.00

+0.30 (1.20%)

As of 04/26/2024 06:33 PM ET

Days: 30 | 90 | 365

Move Your Money Before May 1

From Stansberry Research | Ad

Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?

Click here to get the full story before May 1.

Theratechnologies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2023	Dale Weil	Director	Buy	36,200	C$1.38	C$49,956.00
10/30/2023	Joseph Arena	Director	Buy	10,000	C$0.93	C$9,250.00
10/27/2023	Dawn Svoronos	Director	Buy	15,800	C$1.37	C$21,646.00
10/27/2023	Philippe Dubuc	Senior Officer	Buy	8,000	C$1.36	C$10,855.20
10/21/2022	Joseph Arena	Director	Buy	2,500	C$2.54	C$6,353.25	15,000
7/21/2022	Jocelyn Lafond	Senior Officer	Sell	6,200	C$2.83	C$17,546.00	21,800
7/19/2022	Jocelyn Lafond	Senior Officer	Sell	3,000	C$2.75	C$8,250.00	28,000
5/2/2022	Joseph Arena	Director	Buy	100	C$2.93	C$293.24	7,600
10/25/2021	Dale Weil	Director	Buy	11,470	C$4.39	C$50,353.30	28,170
10/22/2021	Joseph Arena	Director	Buy	2,500	C$4.61	C$11,516.34	7,500
7/30/2021	Joseph Arena	Director	Buy	2,000	C$4.46	C$8,923.20	2,000

Move Your Money Before May 22

From Stansberry Research | Ad

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

SEC Filings (Institutional Ownership Changes) for Theratechnologies (TSE:TH)

50.88% of Theratechnologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Today's Range

Now: N/A

50 Day Range

MA: C$1.93

C$1.64

C$2.29

52 Week Range

Now: N/A

Volume

14,756 shs

Average Volume

37,017 shs

Market Capitalization

C$82.76 million

P/E Ratio

N/A

Dividend Yield

3.76%

Beta

1.73

Who are the company insiders with the largest holdings of Theratechnologies?: Theratechnologies' top insider investors include:
Jocelyn Lafond (Senior Officer)
Joseph Arena (Director)
Dale Weil (Director)
Dawn Svoronos (Director)
Philippe Dubuc (Senior Officer)
Learn More about top insider investors at Theratechnologies.